Iridium Medical Technology Company (IMTC) is an innovative neuron-electronic interface company, and the first to develop high acuity spherical bionic retina, a class III medical device. IMTC develops a proprietary contact lens-shaped 4,000 pixels retinal prosthesis to remedy retinal blindness caused by Retinitis Pigmentosa (RP) and Age-related Macular Degeneration (AMD). IMTC enables patients to recognize faces and objects, read big-print books (font size > 14 pt.), and navigate easily through life by using its 4,000-pixel device.

CORE COMPETENCES

Iridium has grasped the key and patented technologies to effectively interface between electrodes to neurons, including the followings:

1. Microelectrode Technology with high efficiency

2. Electronic Passivation Technology that is biocompatible and implantable

3. Non-planar Electronics and Flexible Technology that can interface with cell’s soft tissue

4. Biomimetics Technology

With the above technologies, we have significant competitive advantages to develop future products in the bioelectronics field to capture the emerging global neurostimulation devices market.

PRIMARY MARKET

There are more than 2 million RP patients worldwide, making it the leading cause of inherited blindness in the world. AMD, with 25 million sufferers worldwide, is the leading cause of blindness in the industrialized world. These patients progressively become blind, and currently there is no medical cure. The number of people that are legally blind and severely impaired due to AMD is 2 million, and from RP roughly 375,000. The population of AMD is growing due to the increased life expectancy of world population. The Lancet reported that the number of AMD patients would approach 200,000,000 at year 2020.

COMPANY INFO

Founded: 2012
Employees: ~30
Parent Company: Theia Medical Technology Co. Ltd (KY)
Contact: info@irmedtech.com
Iridium Medical Technology Company office website

MANAGEMENT TEAM

CEO: Dr. Long-Sheng Fan, PhD in EECS,
University of California, Berkeley

Co-Founder: Dr. Chang-Hao Yang, MD and PhD,
National Taiwan University, Retina Implant Surgery

EVP, Engineering: Dr. J. M. Hong, PhD in Materials Sciences,
University of California, Berkeley

VP, Circuit and System Technology: Dr. Feng-Hsiung Hsu, PhD in CS,
Carnegie Mellon University

VP, Clinical Regulation & Quality Assurance: Dr. Min Sheu, PhD in Bioengineering,
University of Washington

VP, Operations: Mei Jane Hsieh, MLIS,
University of California, Berkeley

CFO: Gwen Chen, CPA,
MBA, University of Denver

AWARDS

2017 Taipei Biotech Awards-Innovation Bronze Medal Award

2015 Taipei Biotech Awards-Technology Transfer Silver Medal Award

2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award

2015 The 12th National Innovation Award